IN2014DN00090A - - Google Patents
Download PDFInfo
- Publication number
- IN2014DN00090A IN2014DN00090A IN90DEN2014A IN2014DN00090A IN 2014DN00090 A IN2014DN00090 A IN 2014DN00090A IN 90DEN2014 A IN90DEN2014 A IN 90DEN2014A IN 2014DN00090 A IN2014DN00090 A IN 2014DN00090A
- Authority
- IN
- India
- Prior art keywords
- pharmaceutical
- parkinson
- disease
- treatment
- composition containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11290320A EP2545905A1 (de) | 2011-07-11 | 2011-07-11 | Neue therapeutische Zusammensetzung mit Apomorphin als aktiver Inhaltsstoff |
PCT/EP2012/002916 WO2013007381A1 (en) | 2011-07-11 | 2012-07-11 | A new therapeutical composition containing apomorphine as active ingredient |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN00090A true IN2014DN00090A (de) | 2015-05-15 |
Family
ID=46514305
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN90DEN2014 IN2014DN00090A (de) | 2011-07-11 | 2012-07-11 |
Country Status (29)
Country | Link |
---|---|
US (4) | US11026938B2 (de) |
EP (2) | EP2545905A1 (de) |
JP (2) | JP6356064B2 (de) |
KR (1) | KR101990897B1 (de) |
CN (2) | CN108434094A (de) |
AU (1) | AU2012283381B2 (de) |
BR (1) | BR112014000306B1 (de) |
CA (1) | CA2841807C (de) |
CL (1) | CL2014000050A1 (de) |
CO (1) | CO6870038A2 (de) |
CR (1) | CR20140005A (de) |
CU (1) | CU24159B1 (de) |
DO (1) | DOP2014000003A (de) |
EA (1) | EA025870B1 (de) |
EC (1) | ECSP14013200A (de) |
GE (1) | GEP20196969B (de) |
GT (1) | GT201400003A (de) |
IL (1) | IL230308A (de) |
IN (1) | IN2014DN00090A (de) |
MA (1) | MA35411B1 (de) |
MX (2) | MX2014000454A (de) |
MY (1) | MY168212A (de) |
NI (1) | NI201400003A (de) |
PE (1) | PE20141539A1 (de) |
SG (1) | SG10201605491PA (de) |
TN (1) | TN2014000001A1 (de) |
UA (1) | UA113962C2 (de) |
WO (1) | WO2013007381A1 (de) |
ZA (1) | ZA201309711B (de) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2545905A1 (de) * | 2011-07-11 | 2013-01-16 | Britannia Pharmaceuticals Limited | Neue therapeutische Zusammensetzung mit Apomorphin als aktiver Inhaltsstoff |
EP3456315A1 (de) | 2012-06-05 | 2019-03-20 | Neuroderm Ltd | Zusammensetzungen mit apomorphin und organischen säuren und verwendungen davon |
EP2918266A1 (de) | 2014-03-11 | 2015-09-16 | CDRD Berolina AB | Zusammensetzung mit Dopaminagonist und L-DOPA-Derivat zur Parkinson-Behandlung |
EP2979688A1 (de) * | 2014-08-01 | 2016-02-03 | Britannia Pharmaceuticals Limited | Zusammensetzung mit Apomorphin und divalentem Metallkation |
RU2017123762A (ru) * | 2014-12-23 | 2019-01-24 | Нейродерм Лтд | Кристаллические формы апоморфина и их применение |
MA43042A (fr) | 2015-09-28 | 2018-08-08 | Ever Neuro Pharma Gmbh | Composition aqueuse d'apomorphine pour une administration sous-cutanée |
WO2020243538A1 (en) * | 2019-05-31 | 2020-12-03 | Primo Pharmatech Llc | Unit dosage form for transmucosal drug delivery of an active pharmaceutical ingredient |
CN114980896A (zh) * | 2019-08-07 | 2022-08-30 | 阿克里普斯一有限公司 | (6AS)-6-甲基-5,6,6A,7-四氢-4H-二苯并[de,g]喹啉-10,11-二醇的药物组合物 |
CN115666571A (zh) | 2020-05-20 | 2023-01-31 | 美德阿利克斯株式会社 | 含有阿扑吗啡的经皮吸收型制剂 |
WO2022271537A1 (en) * | 2021-06-25 | 2022-12-29 | President And Fellows Of Harvard College | Compositions and methods relating to injectable microemulsions |
WO2023242355A1 (en) | 2022-06-15 | 2023-12-21 | Ever Neuro Pharma Gmbh | Apomorphine prodrugs and uses thereof |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU1662566A1 (ru) * | 1988-03-05 | 1991-07-15 | Всесоюзный Научно-Исследовательский Институт Биотехнологии | Способ стабилизации инъекционного раствора апоморфина |
JP2822049B2 (ja) * | 1989-02-02 | 1998-11-05 | ゼリア新薬工業株式会社 | 水性製剤組成物 |
ATE290864T1 (de) * | 1993-03-26 | 2005-04-15 | Franciscus Wilhelmus He Merkus | Pharmazeutische zusammensetzungen zur intranasalen verabreichung von dihydroergotamin |
US6121276A (en) * | 1994-04-22 | 2000-09-19 | Pentech Pharmaceuticals, Inc. | Apomorphine-containing dosage forms for ameliorating male erectile dysfunction |
US5562917A (en) * | 1994-12-23 | 1996-10-08 | Pentech Pharmaceuticals, Inc. | Transdermal administration of apomorphine |
US5945117A (en) | 1998-01-30 | 1999-08-31 | Pentech Pharmaceuticals, Inc. | Treatment of female sexual dysfunction |
JP3723857B2 (ja) * | 1998-02-04 | 2005-12-07 | 日本ケミカルリサーチ株式会社 | ヒト成長ホルモン含有水性医薬組成物 |
US6011043A (en) | 1998-06-19 | 2000-01-04 | Schering Corporation | Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction |
US6436950B1 (en) * | 1998-08-14 | 2002-08-20 | Nastech Pharmaceutical Company, Inc. | Nasal delivery of apomorphine |
US5994363A (en) * | 1998-08-24 | 1999-11-30 | Pentech Pharmaceuticals, Inc. | Amelioration of apomorphine adverse effects |
BR0005797A (pt) * | 2000-03-20 | 2001-10-16 | Abbott Lab | Métodos para o tratamento de disfunção sexual com apomorfina em nìveis de concentração plasmática especificados |
US20030008878A1 (en) | 2001-03-09 | 2003-01-09 | Cowart Marlon D. | Benzimidazoles that are useful in treating sexual dysfunction |
US20020169166A1 (en) | 2001-03-09 | 2002-11-14 | Cowart Marlon D. | Benzimidazoles that are useful in treating sexual dysfunction |
ITMI20011321A1 (it) * | 2001-06-22 | 2002-12-22 | Chiesi Farma Spa | Composizione farmaceutica in forma di microemulsione atta alla somministrazione per via transdermale di apomorfina utile nel trattamento del |
US20040028613A1 (en) | 2001-06-25 | 2004-02-12 | Nastech Pharmaceutical Company Inc | Dopamine agonist formulations for enhanced central nervous system delivery |
PE20030762A1 (es) | 2001-12-18 | 2003-09-05 | Schering Corp | Compuestos heterociclicos como antagonistas nk1 |
US6939094B2 (en) | 2003-01-28 | 2005-09-06 | Macro Technologies Inc. | Autonomous power interface for modifying limited rotation speed of a machine |
WO2004089988A2 (en) | 2003-04-03 | 2004-10-21 | Protein Design Labs, Inc | Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation |
US20050090518A1 (en) * | 2003-10-24 | 2005-04-28 | Nastech Pharmaceutical Company Inc. | Method for treating parkinson's disease using apomorphine and apomorphine prodrugs |
EP1714648A4 (de) * | 2004-02-09 | 2010-05-26 | Aska Pharm Co Ltd | Kombinationsarzneimittel |
WO2007134876A2 (en) | 2006-05-24 | 2007-11-29 | Bayer Schering Pharma Aktiengesellschaft | HIGH AFFINITY HUMAN AND HUMANIZED ANTI-α5β1 INTEGRIN FUNCTION BLOCKING ANTIBODIES WITH REDUCED IMMUNOGENICITY |
US20080171072A1 (en) * | 2006-08-11 | 2008-07-17 | Frank Burczynski | Ocular inserts containing apomorphine |
US8741918B2 (en) * | 2007-06-21 | 2014-06-03 | Veroscience Llc | Parenteral formulations of dopamine agonists |
EP2057982A1 (de) * | 2007-11-09 | 2009-05-13 | Archimedes Development Limited | Intranasale Zusammensetzungen |
CN101712675B (zh) * | 2008-10-07 | 2013-07-03 | 江苏恒谊药业有限公司 | 苯并含氮杂环衍生物及其在治疗神经精神疾病药物的应用 |
EP2545905A1 (de) * | 2011-07-11 | 2013-01-16 | Britannia Pharmaceuticals Limited | Neue therapeutische Zusammensetzung mit Apomorphin als aktiver Inhaltsstoff |
-
2011
- 2011-07-11 EP EP11290320A patent/EP2545905A1/de not_active Withdrawn
-
2012
- 2012-07-11 BR BR112014000306-8A patent/BR112014000306B1/pt active IP Right Grant
- 2012-07-11 CU CU20140005A patent/CU24159B1/es active IP Right Grant
- 2012-07-11 CA CA2841807A patent/CA2841807C/en active Active
- 2012-07-11 MY MYPI2014000016A patent/MY168212A/en unknown
- 2012-07-11 CN CN201810378574.0A patent/CN108434094A/zh active Pending
- 2012-07-11 GE GEAP201213377A patent/GEP20196969B/en unknown
- 2012-07-11 SG SG10201605491PA patent/SG10201605491PA/en unknown
- 2012-07-11 UA UAA201400117A patent/UA113962C2/uk unknown
- 2012-07-11 CN CN201280034745.9A patent/CN103826612B/zh active Active
- 2012-07-11 JP JP2014519451A patent/JP6356064B2/ja active Active
- 2012-07-11 EA EA201400067A patent/EA025870B1/ru not_active IP Right Cessation
- 2012-07-11 WO PCT/EP2012/002916 patent/WO2013007381A1/en active Application Filing
- 2012-07-11 PE PE2014000051A patent/PE20141539A1/es active IP Right Grant
- 2012-07-11 IN IN90DEN2014 patent/IN2014DN00090A/en unknown
- 2012-07-11 KR KR1020147001302A patent/KR101990897B1/ko active IP Right Grant
- 2012-07-11 MX MX2014000454A patent/MX2014000454A/es unknown
- 2012-07-11 AU AU2012283381A patent/AU2012283381B2/en active Active
- 2012-07-11 EP EP12735463.7A patent/EP2731589A1/de active Pending
-
2013
- 2013-12-20 ZA ZA2013/09711A patent/ZA201309711B/en unknown
-
2014
- 2014-01-02 IL IL230308A patent/IL230308A/en active IP Right Grant
- 2014-01-02 TN TNP2014000001A patent/TN2014000001A1/en unknown
- 2014-01-07 CR CR20140005A patent/CR20140005A/es unknown
- 2014-01-09 CL CL2014000050A patent/CL2014000050A1/es unknown
- 2014-01-09 GT GT201400003A patent/GT201400003A/es unknown
- 2014-01-09 NI NI201400003A patent/NI201400003A/es unknown
- 2014-01-09 DO DO2014000003A patent/DOP2014000003A/es unknown
- 2014-01-10 US US14/152,000 patent/US11026938B2/en active Active
- 2014-01-10 MX MX2021010046A patent/MX2021010046A/es unknown
- 2014-02-03 MA MA36727A patent/MA35411B1/fr unknown
- 2014-02-04 CO CO14022989A patent/CO6870038A2/es unknown
- 2014-02-11 EC EC2014013200A patent/ECSP14013200A/es unknown
-
2016
- 2016-06-30 US US15/199,070 patent/US20160310480A1/en not_active Abandoned
- 2016-12-08 JP JP2016238705A patent/JP2017081947A/ja active Pending
-
2017
- 2017-12-13 US US15/840,585 patent/US20180098981A1/en not_active Abandoned
-
2021
- 2021-04-30 US US17/245,209 patent/US11766431B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014DN00090A (de) | ||
NZ608116A (en) | Triazine-oxadiazoles | |
UA110354C2 (uk) | Противірусні сполуки | |
IN2014MN02598A (de) | ||
GEP201706620B (en) | NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS | |
IN2014MN01755A (de) | ||
GEP20146146B (en) | Pyrrolopyrimidine compounds as inhibitors of cdk4/6 | |
UA109220C2 (uk) | Похідні (4-фенілімідазол-2-іл)етиламіну як модулятори натрієвих каналів | |
IN2014CN04530A (de) | ||
IN2015DN01119A (de) | ||
PH12015502802A1 (en) | Formulation comprising a hypolipidemic agent | |
IN2012DN02139A (de) | ||
PH12016501977A1 (en) | 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES | |
MX364400B (es) | Compuestos de tetraciclina. | |
WO2012135615A3 (en) | Enopeptins, uses thereof, and methods of synthesis thereto | |
IN2012DN02502A (de) | ||
IN2014DN05972A (de) | ||
MX2013002620A (es) | Novedosas n-hidroxi-benzamidas para el tratamiento del cancer. | |
EA201490573A1 (ru) | Соединение бензотиазолона | |
IN2013DN02555A (de) | ||
MX2016004909A (es) | Composicion que contiene eugenol como principio activo para prevenir o tratar la dermatitis atopica. | |
IN2015DN01329A (de) | ||
MY164880A (en) | Process for the preparation of isoxazolyl-methoxy-nicotinic acids | |
MX2013012773A (es) | Sustancias farmacologicas, composiciones farmaceuticas y metodos para la preparacion de las mismas. | |
IN2014MN02433A (de) |